Journal of Infectious Diseases
Volume 205 Issue 5 March 1, 2012
http://www.journals.uchicago.edu/toc/jid/current

EDITORIAL COMMENTARIES
Kathleen M. Neuzil
Influenza Vaccines: More Options and More Opportunities
J Infect Dis. (2012) 205(5): 700-701 doi:10.1093/infdis/jir646
(See the article by Ferguson et al, on pages 733–44.)

Extract
Influenza, whether seasonal or pandemic, causes substantial morbidity and mortality. Today, vaccines are the foundation of influenza prevention. Globally, influenza vaccine manufacturing capacity is at an all-time high [1], as are the number and types of influenza vaccines available on the market and in development. In the United States, in addition to the live attenuated and inactivated subunit and split influenza vaccines, a high-dose inactivated vaccine for persons aged ≥65 years, and an intradermally administered inactivated vaccine for persons aged 18–64 years have been recently licensed for seasonal use. This is remarkable progress, considering that as recently as the 2004–2005 influenza season, only one inactivated vaccine was available on the US market [2]. In the United States, all of these vaccines are produced in eggs, although cell-based inactivated and recombinant vaccines are in the late stages of development. Outside the United States, additional inactivated vaccines are licensed for seasonal use, including those manufactured in cell culture, subvirion vaccines combined with the oil-in-water adjuvant MF59 for persons aged ≥65 years, and whole virus and virosomal vaccines. During the 2009 H1N1 pandemic, many countries, not including the United States, also licensed and used monovalent inactivated vaccines adjuvanted with an oil-in-water adjuvant, either AS03 or MF59.

When compared with other vaccines, the range of influenza vaccines that are licensed or in development is unprecedented. The robust market and development pipeline are …
VIRUSES
Murdo Ferguson, George Risi, Matthew Davis, Eric Sheldon, Mira Baron, Ping Li, Miguel Madariaga, Louis Fries, Olivier Godeaux, and David Vaughn
Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
J Infect Dis. (2012) 205(5): 733-744 doi:10.1093/infdis/jir641